SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE
Continuously expanding the scope of potential indications for SN1011 HONG KONG, June 9, 2022 – (ACN Newswire) – SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”, stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is […]